PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Journal of Movement Disorders10.14802/jmd.18005201811265-71Amantadine and the Risk of Dyskinesia in Patients with Early Parkinson’s Disease: An Open-Label, Pragmatic TrialAryun Kim, Young Eun Kim, Ji Young Yun, Han-Joon Kim, Hui-Jun Yang, Woong-Woo Lee, Chae Won Shin, Hyeyoung Park, Yu Jin Jung, Ahro Kim, Yoon Kim, Mihee Jang, Beomseok Jeonhttp://e-jmd.org/upload/jmd-18005.pdf, http://e-jmd.org/journal/view.php?doi=10.14802/jmd.18005, http://www.e-jmd.org/upload/jmd-18005.pdf
Journal of Parkinson's Disease10.3233/jpd-1918412020102543-558EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson’s DiseaseCaroline M. Tanner, Rajesh Pahwa, Robert A. Hauser, Wolfgang H. Oertel, Stuart H. Isaacson, Joseph Jankovic, Reed Johnson, Dustin Chernick, Jean Hubblehttps://content.iospress.com/download?id=10.3233/JPD-191841
Journal of the Neurological Sciences10.1016/j.jns.2017.08.10082017381355ADS-5102 provided reduction in motor complications in Parkinson’s disease patients with levodopa-induced dyskinesia switched from amantadine IR: Subgroup analysis from open-label study (ease LID 2)S. Isaacson, R. Pahwa, C. Tanner, S. Fahn, A. Espay, C. Trenkwalder, R. Patnihttps://api.elsevier.com/content/article/PII:S0022510X17315058?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0022510X17315058?httpAccept=text/plain
Parkinsonism & Related Disorders10.1016/j.parkreldis.2017.11.049201846e14-e15The association between early treatment with amantadine and delayed onset of levodopa-induced dyskinesia in patients with Parkinson’s diseaseT.L. Wu, C.C. Wang, F.J. Lin, R.M. Wuhttps://api.elsevier.com/content/article/PII:S1353802017304728?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1353802017304728?httpAccept=text/plain
Journal of Parkinson's Disease10.3233/jpd-171134201773511-522ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety StudyRobert A. Hauser, Rajesh Pahwa, Caroline M. Tanner, Wolfgang Oertel, Stuart H. Isaacson, Reed Johnson, Larissa Felt, Mary Jean Stempienhttps://content.iospress.com/download?id=10.3233/JPD-171134
Clinical Neurophysiology10.1016/j.clinph.2006.11.12920071184e53Early intervention in parkinson’s disease with cabergoline – Results of an open-label long-term trial with focus on sleep disturbancesW. Jost, M. Ueberallhttps://api.elsevier.com/content/article/PII:S1388245706016610?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1388245706016610?httpAccept=text/plain
CNS Drugs10.1007/s40263-018-0552-22018328797-806Amantadine Extended-Release (GOCOVRI™): A Review in Levodopa-Induced Dyskinesia in Parkinson’s DiseaseJulia Paik, Susan J. Keamhttp://link.springer.com/article/10.1007/s40263-018-0552-2/fulltext.html, http://link.springer.com/content/pdf/10.1007/s40263-018-0552-2.pdf, http://link.springer.com/content/pdf/10.1007/s40263-018-0552-2.pdf
Therapeutics and Clinical Risk Management10.2147/tcrm.s1444812018Volume 14665-673Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson's diseaseVibhash Sharma, Kelly Lyons, Rajesh Pahwahttps://www.dovepress.com/getfile.php?fileID=41489, https://www.dovepress.com/getfile.php?fileID=41489
Archives of Gerontology and Geriatrics10.1016/j.archger.2008.08.0042009491e40-e44Tolcapone in elderly patients with Parkinson’s disease: A prospective open-label multicenter non-interventional trialGeorg Ebersbach, Alexander Storchhttps://api.elsevier.com/content/article/PII:S0167494308001684?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0167494308001684?httpAccept=text/plain
Biological Psychiatry10.1016/0006-3223(91)91015-j199129965An open-label trial of buspirone in the treatment of tardive dyskinesiahttps://api.elsevier.com/content/article/PII:000632239191015J?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:000632239191015J?httpAccept=text/plain